Albany Molecular Research, Inc. (NASDAQ:AMRI) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Friday.

A number of other analysts have also recently weighed in on the company. Morgan Stanley cut Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price target on the stock. in a research report on Thursday, May 11th. They noted that the move was a valuation call. William Blair reiterated an “outperform” rating on shares of Albany Molecular Research in a research report on Tuesday, May 23rd. First Analysis cut Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research report on Monday, June 12th. Finally, J P Morgan Chase & Co cut Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. Five analysts have rated the stock with a hold rating, The stock presently has a consensus rating of “Hold” and an average target price of $18.00.

Shares of Albany Molecular Research (AMRI) traded up 0.05% during trading on Friday, reaching $21.76. The company had a trading volume of 629,856 shares. Albany Molecular Research has a 12 month low of $13.01 and a 12 month high of $22.17. The stock has a 50 day moving average price of $21.70 and a 200 day moving average price of $18.08. The firm’s market capitalization is $906.65 million.

ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/13/albany-molecular-research-inc-amri-upgraded-to-hold-at-bidaskclub.html.

A number of institutional investors have recently bought and sold shares of the company. Virtu KCG Holdings LLC acquired a new position in Albany Molecular Research during the second quarter worth approximately $293,000. Parametric Portfolio Associates LLC raised its position in Albany Molecular Research by 24.5% in the second quarter. Parametric Portfolio Associates LLC now owns 36,527 shares of the biotechnology company’s stock worth $793,000 after buying an additional 7,187 shares in the last quarter. California Public Employees Retirement System raised its position in Albany Molecular Research by 4.2% in the second quarter. California Public Employees Retirement System now owns 94,900 shares of the biotechnology company’s stock worth $2,059,000 after buying an additional 3,800 shares in the last quarter. Vanguard Group Inc. raised its position in Albany Molecular Research by 18.3% in the second quarter. Vanguard Group Inc. now owns 1,561,105 shares of the biotechnology company’s stock worth $33,875,000 after buying an additional 241,050 shares in the last quarter. Finally, Northern Trust Corp raised its position in Albany Molecular Research by 4.3% in the second quarter. Northern Trust Corp now owns 355,860 shares of the biotechnology company’s stock worth $7,722,000 after buying an additional 14,765 shares in the last quarter. 73.43% of the stock is currently owned by institutional investors.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.